Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-06
DOI
10.1002/cncr.32468
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Programmed death ligand 1 expression and CD8 + tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer
- (2018) Jie Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
- (2018) Kim A. Brogden et al. BMC CANCER
- Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
- (2018) Aya Nakaya et al. International Journal of Clinical Oncology
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer
- (2018) Tatsunori Kiriu et al. PLoS One
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Identifying and managing the adverse effects of immune checkpoint blockade
- (2018) Arthur Winer et al. Journal of Thoracic Disease
- Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis
- (2018) DJ Szor et al. Clinics
- Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations
- (2018) Maria I. Toki et al. Journal of Thoracic Oncology
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer
- (2018) Takayuki Takeda et al. Thoracic Cancer
- First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
- (2018) J. Nicholas Bodor et al. Journal of Oncology Practice
- Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
- (2018) Vamsidhar Velcheti et al. PLoS One
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- P1.07-039 Blood Biomarkers Correlate with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti PD-1 Antibodies
- (2017) A. Soyano et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients
- (2017) Xu Liu et al. MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
- (2017) Olivier Bylicki et al. Targeted Oncology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
- (2016) Elisabeth Brambilla et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
- (2013) Nancy E. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
- (2012) S. Cedrés et al. Clinical & Translational Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
- (2010) Giorgio Scagliotti et al. Journal of Thoracic Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started